The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
Official Title: A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Study ID: NCT02206334
Brief Summary: This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy in treating patients with breast cancer, non-small cell lung cancer, or prostate cancer that has spread to other parts of the body. Stereotactic body radiation therapy delivers fewer, tightly-focused, high doses of radiation therapy to all known sites of cancer in the body while minimizing radiation exposure of surrounding normal tissue.
Detailed Description: PRIMARY OBJECTIVES: I. To determine the recommended stereotactic body radiation therapy (SBRT) dose for each of the metastatic locations being treated given the individual and overlapping fields when multiple metastases are treated with SBRT in a national clinical trials network setting. SECONDARY OBJECTIVES: I. To estimate rates of \>= grade 3 Common Terminology Criteria for Adverse Events (CTCAE), version (v.) 4.0 adverse events other than a dose-limiting toxicity (DLT) which is possibly, probably, or definitely related to treatment and which occurs within 6 months from the start of SBRT to multiple metastases. II. To estimate the rates of long-term adverse events occurring up to 2 years from the end of SBRT. III. To explore the most appropriate and clinically relevant technological parameters to ensure quality and effectiveness throughout radiation therapy processes, including imaging, simulation, patient immobilization, target and critical structure definition, treatment planning, image guidance and delivery. OUTLINE: Patients undergo 3-5 fractions of image-guided stereotactic body radiation therapy to all existing metastases over 1-3 weeks with at least 40 hours between treatments for an individual metastasis. After completion of study treatment, patients are followed up at 35-45 days and then every 3 months for 2 years.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States
Banner University Medical Center - Tucson, Tucson, Arizona, United States
City of Hope Comprehensive Cancer Center, Duarte, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Sutter Medical Center Sacramento, Sacramento, California, United States
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
University of Colorado Hospital, Aurora, Colorado, United States
Poudre Valley Hospital, Fort Collins, Colorado, United States
University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
University of Florida Health Science Center - Jacksonville, Jacksonville, Florida, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
Grady Health System, Atlanta, Georgia, United States
Emory University Hospital Midtown, Atlanta, Georgia, United States
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Northwest Community Hospital, Arlington Heights, Illinois, United States
Northwestern University, Chicago, Illinois, United States
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Decatur Memorial Hospital, Decatur, Illinois, United States
Loyola University Medical Center, Maywood, Illinois, United States
OSF Saint Francis Medical Center, Peoria, Illinois, United States
Memorial Medical Center, Springfield, Illinois, United States
Southwest Illinois Health Services LLP, Swansea, Illinois, United States
Saint Vincent Anderson Regional Hospital/Cancer Center, Anderson, Indiana, United States
Parkview Hospital Randallia, Fort Wayne, Indiana, United States
IU Health Methodist Hospital, Indianapolis, Indiana, United States
Iowa Methodist Medical Center, Des Moines, Iowa, United States
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
UM Upper Chesapeake Medical Center, Bel Air, Maryland, United States
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
Boston Medical Center, Boston, Massachusetts, United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
GenesisCare USA - Clarkston, Clarkston, Michigan, United States
Henry Ford Hospital, Detroit, Michigan, United States
GenesisCare USA - Farmington Hills, Farmington Hills, Michigan, United States
McLaren Cancer Institute-Flint, Flint, Michigan, United States
McLaren Cancer Institute-Macomb, Mount Clemens, Michigan, United States
McLaren Cancer Institute-Northern Michigan, Petoskey, Michigan, United States
Saint Joseph Mercy Oakland, Pontiac, Michigan, United States
GenesisCare USA - Troy, Troy, Michigan, United States
Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States
Mercy Hospital, Coon Rapids, Minnesota, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Virtua Memorial, Mount Holly, New Jersey, United States
Cooper CyberKnife Center, Mount Laurel, New Jersey, United States
Community Medical Center, Toms River, New Jersey, United States
Virtua Voorhees, Voorhees, New Jersey, United States
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
Montefiore Medical Center - Moses Campus, Bronx, New York, United States
Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States
University of Rochester, Rochester, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States
Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States
Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States
Reading Hospital, West Reading, Pennsylvania, United States
Medical University of South Carolina, Charleston, South Carolina, United States
Self Regional Healthcare, Greenwood, South Carolina, United States
Ogden Regional Medical Center, Ogden, Utah, United States
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Zablocki Veterans Administration Medical Center, Milwaukee, Wisconsin, United States
Cross Cancer Institute, Edmonton, Alberta, Canada
CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada
CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
Jewish General Hospital, Montreal, Quebec, Canada
Kantonsspital Aarau, Aarau, , Switzerland
Name: Steven Chmura
Affiliation: NRG Oncology
Role: PRINCIPAL_INVESTIGATOR